Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix

Elagolix is the first oral gonadotropin-releasing hormone antagonist that entered clinical development and received regulatory approval for the management of women with endometriosis and heavy menstrual bleeding associated with uterine fibroids in combination with a hormonal add-back therapy. This m...

Full description

Saved in:
Bibliographic Details
Main Author: Kristof Chwalisz, M.D., Ph.D (Author)
Format: Book
Published: Elsevier, 2023-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_4be9a7574ba34e8082fc0e2d31f36784
042 |a dc 
100 1 0 |a Kristof Chwalisz, M.D., Ph.D.  |e author 
245 0 0 |a Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix 
260 |b Elsevier,   |c 2023-06-01T00:00:00Z. 
500 |a 2666-3341 
500 |a 10.1016/j.xfre.2023.02.002 
520 |a Elagolix is the first oral gonadotropin-releasing hormone antagonist that entered clinical development and received regulatory approval for the management of women with endometriosis and heavy menstrual bleeding associated with uterine fibroids in combination with a hormonal add-back therapy. This mini review aims to summarize the key clinical studies that led to its regulatory approval. 
546 |a EN 
690 |a Elagolix 
690 |a GnRH antagonist 
690 |a endometriosis 
690 |a uterine fibroids 
690 |a Diseases of the genitourinary system. Urology 
690 |a RC870-923 
690 |a Gynecology and obstetrics 
690 |a RG1-991 
655 7 |a article  |2 local 
786 0 |n F&S Reports, Vol 4, Iss 2, Pp 65-72 (2023) 
787 0 |n http://www.sciencedirect.com/science/article/pii/S2666334123000107 
787 0 |n https://doaj.org/toc/2666-3341 
856 4 1 |u https://doaj.org/article/4be9a7574ba34e8082fc0e2d31f36784  |z Connect to this object online.